Arch Biopartners enrolls first patient at Royal Columbian Hospital in AKI Phase II trial

On 2026-05-22, Arch Biopartners announced that Royal Columbian Hospital in New Westminster, Canada, had dosed its first patient in the company’s Phase II trial of LSALT peptide for cardiac surgery-associated acute kidney injury. The article said this was the fourth Canadian site to begin dosing in the ongoing study.